HCPCS code J9301: Obinutuzumab, per 10 mg2026 Medicare rate & RVUs in Washington
Reports obinutuzumab, an intravenous antibody used in certain chronic lymphocytic leukemia and follicular lymphoma regimens, in 10 mg units.
CMS doesn’t publish an office rate for J9301 in Washington.
Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.
Your location
On this page 9 sections
What J9301 covers
Obinutuzumab is an intravenous monoclonal antibody that targets CD20 on B cells. Oncology practices and hospital infusion departments report it when administering the drug as part of an applicable treatment regimen for chronic lymphocytic leukemia or follicular lymphoma. Depending on the indication and regimen, it may be given with other anticancer drugs or as maintenance treatment. The drug code identifies the medication, not the infusion service.
CMS assigns this code physician fee schedule status E, meaning it is excluded from the physician fee schedule. When Medicare covers the drug, it is treated as a Part B drug and generally priced through CMS’s quarterly Average Sales Price drug files. Coverage is left to the Medicare contractor’s judgment. Each unit represents 10 mg; for example, 1,000 mg corresponds to 100 units. Report the applicable infusion administration service separately when supported by the encounter.
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Where J9301 pays more and less in Washington
| Payment locality | Office | Facility |
|---|---|---|
| King County, WA | Unavailable | Unavailable |
| Rest of Washington | Unavailable | Unavailable |
How the J9301 rate is calculated
Each of J9301’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.
How the rate is built · J9301
RVUs × geographic indexes × conversion factor
Work0.00
0.00 RVUs× 1.000 GPCI
Practice expense0.00
0.00 RVUs× 1.000 GPCI
Malpractice0.00
0.00 RVUs× 1.000 GPCI
Adjusted RVUs
0.0000
Conversion factor
$33.4009
Medicare rate
$0.00
Every GPCI starts at 1.000, the national rate. Enter a ZIP or drag a slider.
Payment rules and modifiers for J9301
J9301 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.
Place of service · J9301
Which rate does Medicare pay?
The POS code on the claim line (CMS-1500 box 24B).
POS 11 · non-facility rate · national
—
J9301 isn’t priced in this setting.
J9301 compared with similar codes
Compare codes · National
4 codes, side by side
How to choose
- J9312Rituximab injectionPer 10 mg
- J9312 identifies rituximab, not obinutuzumab. Use the code for the drug administered, even when treatment settings overlap.
- J9311Rituximab-hyaluronidasePer 10 mg
- J9311 identifies rituximab with hyaluronidase for subcutaneous administration. J9301 identifies intravenous obinutuzumab.
- J9302Ofatumumab injectionPer 10 mg
- J9302 identifies ofatumumab, a different antibody drug used in certain chronic lymphocytic leukemia treatment settings; it is not obinutuzumab.
J9301 billing questions
How many units should be reported?
Each unit represents 10 mg of obinutuzumab. A 1,000 mg dose corresponds to 100 units.
Does this code include the infusion service?
No. This code identifies the drug; report the applicable infusion administration service separately when supported by the encounter.
How does Medicare price this drug when it is covered?
CMS excludes the code from the physician fee schedule. When Medicare covers it, the drug is generally priced through CMS’s quarterly ASP drug files as a Part B drug.
Does this code guarantee Medicare coverage?
No. Coverage is left to the Medicare contractor’s judgment.
How is this different from rituximab?
Obinutuzumab and rituximab are different drugs, each with its own HCPCS code. Select the code for the drug actually administered.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.
CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027
Fee sheets · Coming soon
Put J9301 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist